Radioactive 'Tumor Hunter' drug tested in advanced breast cancer patients
NCT ID NCT04529044
Summary
This study is testing a new, targeted radioactive drug called 177Lu-DOTATATE in patients with advanced breast cancer that has spread or returned. The drug is designed to seek out and attach to specific cancer cells, delivering radiation directly to the tumor to try to shrink it and control the disease. The trial will enroll about 10 patients to see how well the treatment works and how safe it is.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE IV BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.